# 510(k) Summary - Premier Hb9210™

# 510(k) Number Assigned:

# Introduction:

Trinity Biotech hereby submits this summary for the Premier Hb9210 ™ traditional 510(k) in accordance with the requirements of 21 CFR 807.92 for the demonstration of safety and effectiveness and substantial equivalence to the patented K891235 boronate affinity HPLC analyzer and HbA1c assay.

# Submitter and Owner:

Trinity Biotech 4231 E. 75th Terrace Kansas City, MO 64132 USA

Contact Person:Britt Einspahr, Manager of Quality Assurance & Compliance   
Email: Britt. Einspahr@TrinityUSA.Com   
Phone: 716-483-7402   
Fax: 816-214-4410   
Contact Person:Bonnie DeJoy, Corporate VP of RA (Official Correspondent)   
Email: Bonnie.DeJoy@TrinityUSA.Com   
Phone: 716-483-3851 Extension 1030   
Fax: 716-488-1990

Date Prepared: 8 July 2011

Proprietary Name: Premier Hb9210™ HbA1c Analyzer

# Device Name:

Common Names: Premier Hb9210™ Premier - HbA1c Premier - A1c

Classification Name: Glycosylated Hemoglobin Assay

Classification: Class II, IVD

# Product Code: LCP

# Device Description:

The Premier Hb9210™M is an update of the predicate HPLC device, the Ultra2, which is the current model under K891235. The Premier Hb9210™M is a compact, integrated HPLC system and workstation with the Trinity Biotech AFFiNITY Software for the quantitative determination of glycated hemoglobin using the patented boronate affinity chemistry with high performance liquid chromatography.

# Intended Use:

The Premier Hb9210™m system is intended for the quantitative measurement of hemoglobin A1c (HbA1c) in human capillary and venous whole blood. HbA1c is used for the monitoring of long-term glycemic control in individuals with diabetes mellitus. For in vitro diagnostic use only."

Predicate Device: K891235 - Boronate Affinity HPLC Method - Current Model: ultra²

Comparison to Predicate:

The following table provides comparison of the Premier Hb9210™ and HbA1c assay to the predicate device.

<table><tr><td colspan="1" rowspan="1">Aspect or Feature</td><td colspan="1" rowspan="1">Predicate(K891235)</td><td colspan="1" rowspan="1">Premier Hb9210 T</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">For the quantitative measurement of thepercentage of total glycated hemoglobins inwhole blood. For in vitro diagnostic use.</td><td colspan="1" rowspan="1">The Premier Hb9210 ™ system is intendedfor the quantitative measurement ofhemoglobin A1c (HbA1c) in human capillaryand venous whole blood. HbA1c is used forthe monitoring of long-term glycemic controlin individuals with diabetes mellitus. For invitro diagnostic use only."</td></tr><tr><td colspan="1" rowspan="1">Chemistry</td><td colspan="1" rowspan="1">Patented Boronate Affinity</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Types</td><td colspan="1" rowspan="1">Venous EDTAor Finger Stick</td><td colspan="1" rowspan="1">Venous EDTA, Heparin or Sodium Fluorideor Finger Stick</td></tr><tr><td colspan="1" rowspan="1">Method</td><td colspan="1" rowspan="1">HPLC</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">HbA1c SpeciesSeparation</td><td colspan="1" rowspan="1">Chromatography</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">InstrumentationControl</td><td colspan="1" rowspan="1">Windows Operating System withProprietary Assay Software</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Automation</td><td colspan="1" rowspan="1">Completely Automated</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Operation</td><td colspan="1" rowspan="1">Continuous</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Column</td><td colspan="1" rowspan="1">Boronate Affinity Matrix</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Column Matrix</td><td colspan="1" rowspan="1">Replenished, Re-Used</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagents</td><td colspan="1" rowspan="1">Boronate Affinity Chemistry</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Solution Phases</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Optical Phases</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">ChromatographyIntegration</td><td colspan="1" rowspan="1">Peak Separation and Area Determination</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Detector UV Wavelength</td><td colspan="1" rowspan="1">413 nm</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Detector UV Light</td><td colspan="1" rowspan="1">Incandescent Lamp</td><td colspan="1" rowspan="1">LED</td></tr><tr><td colspan="1" rowspan="1">Aspect or Feature</td><td colspan="1" rowspan="1">Predicate(K891235)</td><td colspan="1" rowspan="1">Premier Hb9210TM</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">With Each RunCal Data Used For Each Sample</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample ID</td><td colspan="1" rowspan="1">Operator Input orBar Code Reader</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Controls</td><td colspan="1" rowspan="1">With each run per clinicallaboratory policies</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Standards / Traceability</td><td colspan="1" rowspan="1">IFCC, NGSP</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Test Time</td><td colspan="1" rowspan="1">1 Result per 2 Minutes</td><td colspan="1" rowspan="1">1 Result per 1 Minute</td></tr><tr><td colspan="1" rowspan="1">Results Output</td><td colspan="1" rowspan="1">Display and Print</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Printout</td><td colspan="1" rowspan="1">Automatic, User Select</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reporting Units</td><td colspan="1" rowspan="1">% HbA1c (NGSP / DCCT)</td><td colspan="1" rowspan="1">% HbA1c (NGSP /DCCT)mmol/mol (IFCC)</td></tr><tr><td colspan="1" rowspan="1">Equation Used for FinalHbA1c Value</td><td colspan="1" rowspan="1">%HbA1c = 0.588 * %GHb + 1.706</td><td colspan="1" rowspan="1">%HbA1c = 0.588 * %GHb + 1.706mmol/mol = (%HbA1c - 2.15) / 0.0915</td></tr><tr><td colspan="1" rowspan="1">Safety Stds forElectrical Equip for Laband IVD Use</td><td colspan="1" rowspan="1">IEC61010 Certified</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">ElectromagneticCompatibility</td><td colspan="1" rowspan="1">EMC Certified</td><td colspan="1" rowspan="1">Same</td></tr></table>

Intra-run Precision  All sites - Hemolysate: The between-run precision study consists of three hemolysate samples (1:100 dilution), representing normal, decision point and abnormal levels of %HbA1c. They were analyzed on 20 non-consecutive days. One internal and 2 external sites were involved, each site was provided with the same sample set (aliquotted and frozen whole blood) and directed to perform 2 analyses of each sample per run with 2 runs per day (a total of 80 replicates o each level per site, 240 replicates overall. The study lasted 35 calendar days. The estimates of iprecision for each sample result btained from all 3 study sites all results averaged) analyss ae given in the table below:

<table><tr><td rowspan=1 colspan=1>Actual number of days involved in the experiment, andnumber of sites:</td><td rowspan=1 colspan=1>49days, 3 sites</td></tr><tr><td rowspan=1 colspan=1>Actual total number of runs (if applicable):</td><td rowspan=1 colspan=1>120 total runs</td></tr><tr><td rowspan=1 colspan=1>Total number of observations (including controls):</td><td rowspan=1 colspan=1>1200 total observations</td></tr><tr><td rowspan=1 colspan=1>Number of instruments/devices used in the evaluation,and how results were pooled:</td><td rowspan=1 colspan=1>3 instruments, individualvalues not pooled</td></tr><tr><td rowspan=1 colspan=1>Number of reagent lots:</td><td rowspan=1 colspan=1>1 reagent lot number perreagent/column</td></tr><tr><td rowspan=1 colspan=1>Number of calibration cycles and calibration lots:</td><td rowspan=1 colspan=1>14 total recalibrations oncestudy started, 1 lot ofCalibrator used:</td></tr></table>

All Sites:   

<table><tr><td rowspan=1 colspan=1>Concentrations at which claim is made; %HbA1c</td><td rowspan=1 colspan=1>5.76</td><td rowspan=1 colspan=1>7.07</td><td rowspan=1 colspan=1>10.96</td></tr><tr><td rowspan=1 colspan=1>Estimate of repeatability SD, (Sr)</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.09</td></tr><tr><td rowspan=1 colspan=1>Repeatability %CV = (S/mean)*100</td><td rowspan=1 colspan=1>1.26</td><td rowspan=1 colspan=1>0.72</td><td rowspan=1 colspan=1>0.85</td></tr><tr><td rowspan=1 colspan=1>Estimate of within-device precision SD, (St)</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>0.16</td></tr><tr><td rowspan=1 colspan=1>Within-device precision %CV = (ST/mean)*100</td><td rowspan=1 colspan=1>1.62</td><td rowspan=1 colspan=1>1.28</td><td rowspan=1 colspan=1>1.50</td></tr></table>

Intra-run Precision - Individual Sites - Hemolysate: The between-run precision study data for each individual site is as follows:

Site A: External   

<table><tr><td rowspan=1 colspan=1>Concentrations at which claim is made; %HbA1c</td><td rowspan=1 colspan=1>5.70</td><td rowspan=1 colspan=1>7.06</td><td rowspan=1 colspan=1>10.96</td></tr><tr><td rowspan=1 colspan=1>Estimate of repeatability SD, (S)</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.09</td></tr><tr><td rowspan=1 colspan=1>Repeatability %CV = (S/mean)*100</td><td rowspan=1 colspan=1>1.24</td><td rowspan=1 colspan=1>0.79</td><td rowspan=1 colspan=1>0.78</td></tr><tr><td rowspan=1 colspan=1>Estimate of within-device precision SD. (St)</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>0.18</td></tr><tr><td rowspan=1 colspan=1>Within-device precision %CV = (St/mean)*100</td><td rowspan=1 colspan=1>1.84</td><td rowspan=1 colspan=1>1.58</td><td rowspan=1 colspan=1>1.62</td></tr></table>

Site B: External   

<table><tr><td rowspan=1 colspan=1>Concentrations at which claim is made; %HbA1c</td><td rowspan=1 colspan=1>5.71</td><td rowspan=1 colspan=1>7.08</td><td rowspan=1 colspan=1>10.88</td></tr><tr><td rowspan=1 colspan=1>Estimate of repeatability SD, (S,)</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.09</td></tr><tr><td rowspan=1 colspan=1>Repeatability %CV = (S,/mean)*100</td><td rowspan=1 colspan=1>0.85</td><td rowspan=1 colspan=1>0.79</td><td rowspan=1 colspan=1>0.85</td></tr><tr><td rowspan=1 colspan=1>Estimate of within-device precision SD, (St)</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>0.18</td></tr><tr><td rowspan=1 colspan=1>Within-device precision %CV = (ST/mean)*100</td><td rowspan=1 colspan=1>1.47</td><td rowspan=1 colspan=1>1.20</td><td rowspan=1 colspan=1>1.62</td></tr></table>

Site C: Internal   

<table><tr><td rowspan=1 colspan=1>Concentrations at which claim is made; %HbA1c</td><td rowspan=1 colspan=1>5.85</td><td rowspan=1 colspan=1>7.06</td><td rowspan=1 colspan=1>11.03</td></tr><tr><td rowspan=1 colspan=1>Estimate of repeatability SD, (S)</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.10</td></tr><tr><td rowspan=1 colspan=1>Repeatability %CV = (S/mean)*100</td><td rowspan=1 colspan=1>1.68</td><td rowspan=1 colspan=1>0.57</td><td rowspan=1 colspan=1>0.92</td></tr><tr><td rowspan=1 colspan=1>Estimate of within-device precision SD, (S)</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>0.14</td></tr><tr><td rowspan=1 colspan=1>Within-device precision %CV = (ST/mean)*100</td><td rowspan=1 colspan=1>1.55</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>1.27</td></tr></table>

Accuracy - The $r ^ { 2 }$ value when analyzing IFCC HbA1c Standards is 0.9998 and the ² value when analyzing 51 samples vs. ultra² is 0.9976.

Linearity - The demonstrated linearity is from 3.7% - 18.5%HbA1c.

# Substantial

Equivalence: The Trinity Biotech Premier $H b 9 2 1 0 ^ { \pi }$ and the predicate device are based on the same method, technology, materials, and engineering with the Premier $H b  2 1 0 ^ { \mathsf { r m } }$ being a new model in the high performance liquid chromatography boronate afinity product line. All key elements and performance aspects are either identical or functionally equivalent. In conclusion, the Premier Hb9210™ is functionally equivalent and safe and effective for the intended use.

Primus Corporation DBA Trinity Biotech   
$\gamma / 0$ Britt Einspahr   
Manager of Quality Assurance & Compliance   
4231 E $7 5 ^ { \mathrm { t h } }$ Terrace   
Kansas City, MO 64132

Re: K112015

Trade Name: Premier Hb9210   
Regulation Number: 21 CFR 864.7470   
Regulation Name: Glycosylated hemoglobin assay   
Regulatory Class: Class II   
Product Code: LCP   
Dated: October 07, 2011   
Received: October 17, 2011

Dear Britt Einspahr:

We have reviewed your Section $5 1 0 ( \mathrm { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/Medical   
Devices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance...

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm

Sincerely yours,

![](images/af11d6ef78600c89d3a0f5cda4b3856050af738049038a0a6a60f26ff897ccf8.jpg)

Coupney H. Lias, Ph.D.   
Diractor   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): K112015

Device Name: Premier Hb9210

Indications for Use:

The Premier Hb9210 System is intended for the quantitative measurement of hemoglobin A1c (HbA1c) in human capillary and venous whole blood. HbA1c is used for the monitoring of long-term glycemic control in individuals with diabetes mellitus. For in vitro diagnostic use only.

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Page 1 of 1

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety 510(K) K112015